Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer



Status:Recruiting
Conditions:Liver Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/5/2018
Start Date:April 2013
End Date:June 2025

Use our guide to learn which trials are right for you!

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation
therapy to see how well they work compared to sorafenib tosylate alone in treating patients
with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send
the radiation dose directly to the tumor and cause less damage to normal tissue. Giving
sorafenib tosylate together with stereotactic body radiation therapy may kill more tumor
cells.

PRIMARY OBJECTIVES:

I. To determine if stereotactic body radiation therapy (SBRT) improves overall survival in
hepatocellular carcinoma (HCC) patients treated with sorafenib (sorafenib tosylate).

SECONDARY OBJECTIVES:

I. To determine the difference in time to progression (TTP) and progression-free survival
(PFS) in HCC patients treated with sorafenib compared to SBRT followed by sorafenib.

II. To measure differences in toxicity in HCC patients treated with sorafenib versus SBRT
followed by sorafenib.

III. To measure vascular thrombosis response post sorafenib versus SBRT followed by
sorafenib.

IV. To measure differences in health related quality of life (QOL) and quality-adjusted
survival in HCC patients treated with sorafenib compared to SBRT followed by sorafenib.

V. Collection of biospecimens for future correlative studies to investigate differences in
potential biomarkers in patients treated with sorafenib versus SBRT followed by sorafenib.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM 1: Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-28.
Treatment repeats every 28 days for up to 5 years in the absence of disease progression or
unacceptable toxicity.

ARM 2: Patients undergo SBRT every 24-72 hours for a total of 5 fractions over 5 to 15 days.
Within 1-5 days post-SBRT, patients receive sorafenib tosylate PO BID on days 1-28. Treatment
repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable
toxicity.

Patients are followed weekly during SBRT, monthly during sorafenib tosylate and on the
following schedule as a whole from study entry: every 3 months for 3 years, then every 6
months for 2 years and then annually.

Inclusion Criteria:

- Patients must have a diagnosis of HCC by at least one criterion listed below within
360 days prior to study entry:

- Pathologically (histologically or cytologically) proven diagnosis of
HCC,(biopsies are recommended, and are to be submitted for research evaluation if
patients consent)

- At least one solid liver lesion or vascular tumor thrombosis (involving portal
vein, inferior vena cava [IVC] and/or hepatic vein) > 1 cm with arterial
enhancement and delayed washout on multi-phasic computerized tomography (CT) or
magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis
B or C without cirrhosis.

- For patients whose CURRENT disease is vascular only: enhancing vascular
thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early
arterial enhancement and delayed washout on multi-phasic CT or MRI in a patient
with known HCC (diagnosed previously <720 days) using the above criteria.

- Measureable hepatic disease and/or presence of vascular tumor thrombosis (involving
portal vein, IVC and/or hepatic vein) which may not be measureable as per Response
Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within 28 days of
registration

- Appropriate for protocol entry based upon the following minimum diagnostic workup:

- History/physical examination including examination for encephalopathy, ascites,
weight, height, and blood pressure within 14 days prior to study entry

- Assessment by radiation oncologist and medical oncologist or hepatologist who
specializes in treatment of HCC within 28 days prior to study entry

- Pre-randomization Scan (REQUIRED for All Patients): CT scan chest/abdomen/pelvis
or PET CT chest/abdomen/pelvis with multiphasic liver CT or multiphasic liver MR
scan within 28 days prior to study entry. MRI of abdomen and pelvis with contrast
with chest CT is permitted.

- Zubrod performance status 0-2 within 28 days prior to study entry

- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

- Platelets >= 60,000 cells/mm^3

- Hemoglobin >= 8.0 g/dl (note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 times upper
limit of normal (ULN)

- Serum creatinine =< 2 x ULN or creatinine clearance >= 60 mL/min

- Barcelona Clinic Liver Cancer (BCLC) stage: intermediate (B) or advanced (C) within 28
days prior to study entry

- Child-Pugh score A within 14 days prior to study entry

- Women of childbearing potential and male participants must agree to practice adequate
contraception while on study and for at least 6 months following the last dose of
radiation therapy (RT) and for at least 28 days following the last dose of sorafenib
(whichever is later)

- Unsuitable for resection or transplant or radiofrequency ablation (RFA)

- Unsuitable for or refractory to transarterial hepatic chemo-embolization (TACE) or
drug eluting beads (DEB) for any of the following reasons, as described by Raoul et al
(2011):

- Technical contraindications: arteriovenous fistula, including, surgical
portosystemic shunt or spontaneous portosystemic shunt

- Severe reduction in portal vein flow: due to tumor portal vein, IVC or atrial
invasion or bland portal vein occlusion

- Medical contraindications including congestive heart failure, angina, severe
peripheral vascular disease

- Presence of extrahepatic disease

- No response post TACE (or DEB) or progressive HCC despite TACE; prior TACE or DEB
is allowed but must be > 28 days from study entry

- Serious toxicity following prior TACE (or DEB); prior TACE or DEB must be > 28
days from study entry

- Other medical comorbidities making TACE (or DEB) unsafe and/or risky (e.g.
combination of relative contraindications including age > 80 years, tumor > 10
cm, > 50% replacement of the liver by HCC, extensive multinodular bilobar HCC,
biliary drainage)

- Patients treated with prior surgery are eligible for this study if they otherwise meet
eligibility criteria

- Patient must be able to provide study-specific informed consent prior to study entry

Exclusion Criteria:

- Prior invasive malignancy (except non-melanomatous skin cancer and T1 renal cell
carcinoma) unless disease free for a minimum of 2 years (note that carcinoma in situ
of the breast, oral cavity, or cervix are all permissible)

- Prior sorafenib use > 60 days and/or grade 3 or 4 sorafenib related toxicity. Note
that prior chemotherapy for HCC or a different cancer is allowable

- Prior radiotherapy to the region of the liver that would result in overlap of
radiation therapy fields

- Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time

- Severe, active co-morbidity, defined as follows:

- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 6 months PRIOR TO registration

- Transmural myocardial infarction within the last 6 months prior to study entry

- Unstable ventricular arrhythmia within the last 6 months prior to study entry

- Acute bacterial or fungal infection requiring intravenous antibiotics within 28
days prior to study entry

- Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or
variceal bleed within 28 days prior to study entry

- Bleeding within 28 days prior to study entry due to any cause, requiring
transfusion

- Thrombolytic therapy within 28 days prior to study entry. Subcutaneous heparin is
permitted.

- Known bleeding or clotting disorder

- Uncontrolled psychotic disorder

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception; this exclusion is
necessary because the treatment involved in this study may be significantly
teratogenic

- Maximal diameter of any one hepatocellular carcinoma > 15 cm

- Total sum of maximum diameters of each definite parenchymal hepatocellular carcinoma
within the liver or maximum diameter of a single conglomerate HCC > 20 cm

- More than 5 discrete intrahepatic parenchymal foci of HCC

- Direct tumor extension into the stomach, duodenum, small bowel or large bowel

- Measureable common or main branch biliary duct involvement with HCC

- Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC)
> 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph
node or two 2 cm lung lesions); note that benign non-enhancing periportal
lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if
the sum of enlarged nodes is > 2.0 cm

- Prior liver transplant

- HIV positive with CD4 count < (350) cells/microliter. Note that patients who are HIV
positive are eligible, provided they are under treatment with highly active
antiretroviral therapy (HAART) and have a CD4 count ≥ (350) cells/microliter, and no
known detectable viral load, at the time of study entry. Note also that HIV testing is
not required for eligibility for this protocol
We found this trial at
42
sites
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: John P. Hayes
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Benjamin B. Bridges
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Yuhchyau Chen
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Mary U. Feng
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Tracey E. Schefter
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Michael D. Chuong
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Amol K. Narang
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Andrew X. Zhu
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Lisa A. Kachnic
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bridgeport, Connecticut 06606
Principal Investigator: Christopher M. Iannuzzi
Phone: 203-576-6329
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Nitin Ohri
Phone: 718-904-2730
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Christopher J. Anker
Phone: 802-656-4101
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: Neeta K. Venepalli
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Jennifer A. Dorth
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Terence M. Williams
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
(808) 538-9011
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Sunil Krishnan
Phone: 877-312-3961
?
mi
from
Houston, TX
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Anthony El-Khoueiry
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Melbourne, Victoria 3004
?
mi
from
Melbourne,
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: Beth A. Erickson
Phone: 414-805-4380
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Salma K. Jabbour
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Mini J. Elnaggar
Phone: 504-703-8712
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Karyn A. Goodman
Phone: 212-639-7202
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Richmond, Virginia 23249
Principal Investigator: Drew Moghanaki
Phone: 804-675-5646
?
mi
from
Richmond, VA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Jeffrey R. Olsen
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Randa Tao
Phone: 888-424-2100
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Albert J. Chang
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94158
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Smith Apisarnthanarax
Phone: 800-804-8824
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98133
Principal Investigator: Smith Apisarnthanarax
Phone: 412-339-5294
?
mi
from
Seattle, WA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Principal Investigator: Alexander M. Stessin
Phone: 800-862-2215
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Warrenville, Illinois 60555
Principal Investigator: Nasiruddin Mohammed
Phone: 630-315-1918
?
mi
from
Warrenville, IL
Click here to add this to my saved trials